Logoontheleft whitebackground 01
Megill scott headshot

Coriell Life Sciences

Coriell Life Sciences provides the infrastructure allowing meaningful use of genome sequencing for doctors in the care of their patients

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Camden, NJ, USA
  • Currency USD
  • Founded January 2013
  • Employees 6
  • Website coriell.com

Company Summary

Coriell Life Sciences is expert in advising physicians on how to use genomics to understand what medications will work for their patients and which will cause harm. Through partnerships with IBM and sequencing laboratories, CLS has developed an entirely SaaS based platform for drug efficacy reporting that is inexpensive, reimbursed by MediCare and most carriers and provides immediate patient outcome benefit and financial savings.


  • Photo
    President and CEO

    Scott Megill is the President and Chief Executive Officer of Coriell Life Sciences, a recent commercial spin-out from the Coriell Institute for Medical Research. As a founder of CLS, Mr. Megill has led the planning, fundraising and launch of Coriell Life Sciences securing partnerships with IBM, major healthcare systems and the State of New Jersey. Coriell Life Sciences is now poised to bring the age of genome informed medicine into the clinic.

  • Default avatar
    Michael Christman
    Founder & Chairman of the Board

    Dr. Michael Christman is the President and Chief Executive Officer of the Coriell Institute for Medical Research. After taking the helm of the Coriell Institute on June 1, 2007, he established the Coriell Personalized Medicine Collaborative® (CPMC®), an evidence-based research study aimed to determine the utility of using genome information in health management. Dr. Christman has been instrumental in cultivating partnerships with customers.

  • Default avatar
    Joseph Jarvis
    Director of Genetic Risk Reporting

    A quantitative and statistical geneticist by training, Dr. Joseph Jarvis’ previous work focused not only on identifying the genetic variants contributing to complex disease but also the complex interactions among the various alleles and environmental factors such as diet. This expertise is precisely what is necessary to bring Coriell Life Sciences to the forefront in the delivery of

  • Default avatar
    Steve Kradel
    Director of Product Development

    Mr. Kradel is an expert at software development bringing decades of experience building robust, scalable enterprise class application design to the build of CLS's product suite.

  • Default avatar
    Dr. Jeffrey Shaman
    Business Development Manager

    Dr. Shaman is a PhD geneticist with a strong background in clinical laboratory services and business development

  • Default avatar
    James Doherty
    Director of Enterprise Architecture

    Mr. Doherty spent 34 years at IBM Corporation in technical sales and architecture.


  • Default avatar
    Morgan Lewis - Steve Goodman

Previous Investors

  • Default avatar
    Default avatar